The drug levosimendan did not improve survival for patients with decompensated heart failure when compared with a more widely-used treatment for this condition, dobutamine, according to a study in the May 2 issue of JAMA.
Acute decompensated heart failure (ADHF; severe heart failure characterized by inability of the heart to maintain adequate blood circulation) remains a common cause of hospitalization worldwide, but appropriate treatment is not always clear. Dobutamine improves symptoms but has been associated with an increased risk of death and other cardiovascular events, according to background information in the article. In a previous study, secondary analyses indicated that the drug levosimendan was associated with lower risk of death compared to dobutamine.
Alexandre Mebazaa, M.D., Ph.D., of the Université Paris Diderot and Hospital Lariboisière AP-HP, Paris, and colleagues with the SURVIVE trial (Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support) conducted a study in which the primary purpose of the trial was to assess long-term survival outcomes for 1,327 ADHF patients who received levosimendan or dobutamine. The trial was conducted at 75 centers in 9 countries and patients were randomized between March 2003 and December 2004. Patients received either intravenous levosimendan (n = 664) or intravenous dobutamine (n = 663).